Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9684110.26442/20751753.2019.7.190509Research ArticleEffect of antibacterial agent PK/PD index on efficacy of lower urinary tract infection therapyDukhaninAleksandr S.D. Sci. (Med.), Prof.das03@rambler.ruPirogov Russian National Research Medical University15072019217697419012022Copyright © 2019, Consilium Medicum2019The individual pharmacological profile of an antimicrobial drug (AMP) is determined by its pharmacokinetic/pharmacodynamic properties and is referred to as the PK/PD profile. Based on the estimated PK/PD index, various types of antimicrobial activity were identified: concentration-dependent and time-dependent AMP. Fluoroquinolones are antimicrobial agents with a concentration-dependent effect, for which the peak concentration of the active substance is important to achieve a bactericidal effect. Along with the minimum inhibitory concentration, for assessing the microbiological efficacy of ciprofloxacin, an indicator of the minimum concentration preventing mutations, which reflects the presence of the “mutation selection window”, is important. The main obstacle to increasing bioavailability and the formation of maximum plasma concentrations of ciprofloxacin is a “narrow absorption window”. The original prolonged dosage form of ciprofloxacin 1000 mg for a single dose per day (Cifran® OD 1000 mg) is based on FDD technology: flotation, dispersion and diffusion. Due to the higher Cmax values created, the tablet form of the sustained release allows overcoming the “window of selection mutation” of the main uropathogens. The proven reduction in the frequency of therapeutic failures when using the ciprofloxacin 1000 mg dosing regimen 1 time per day is due to the possibility of slowing down the mutation rate and preventing the selection of resistant strains of uropathogens against the background of antimicrobial therapy, as well as increasing adherence to therapy.pharmacokineticspharmacodynamicsantimicrobial resistancefluoroquinolonesciprofloxacindosage formtherapeutic efficacytherapeutic failureфармакокинетикафармакодинамикаантимикробная резистентностьфторхинолоныципрофлоксацинлекарственная формаэффективность терапиитерапевтические неудачи[Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother 2015; 21 (5): 319-29.][Dukhanin A.S, Patrashev D.V, Ogurtsov S.I. Intracellular ph in thymocytes at the early stages of apoptosis and necrosis. Bull Exp Biol Med 1999; 128 (4): 991-3.][Sergeev P.V, Galenko-Yaroshevskii P.A, Khankoeva A.I, Dukhanin A.S. A study of the mechanism of action of befol on Ca2+ metabolism in cardiomyocytes using a fura-2 fluorescent probe. Bull Exp Biol Med 1996; 121 (3): 265-7.][Onufrak N.J, Forrest A, Gonzalez D. Pharmacokinetic and Pharmacodynamic Principles of Anti-Infective Dosing. Clin Ther 2016; 38(9): 1930-47.][Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. Практическое руководство по антиинфекционной химиотерапии. https:// http://www.antibiotic.ru/ab/ @@Strachunsky L.S., Belousov Yu.B., Kozlov S.N. Practical Guide to Anti-infective Chemotherapy. http:// www.antibiotic.ru/ab/ (in Russian).]][Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: A guide for clinicians. J Anaesthesiol Clin Pharmacol 2017; 33 (3): 300-5.][Owens R.C, Shorr A.F. Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 2009; 66 (Suppl. 4): S23-S30.][MacDougall C, Chambers H.F. Aminoglycosides. In: Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13th Ed., edited by Brunton LL, Hilal-Dandan R, Knollmann BC, NewYork, McGraw-Hill Education, 2017; p. 1039-48.][Sab A, Tomas A, Tomić N et al. Pharmacokinetic/pharmacodynamic based dosing of ciprofloxacin in complicated urinary tract infections. Bangladesh J Pharmacol 2015; 10: 621-6.][Szałek E, Tomczak H, Kamińska A et al. The PK/PD index for ciprofloxacin in critically ill patients. Anestezjologia i Ratownictwo 2010; 4: 409-13.][Eyler R.F, Shvets K. Clinical Pharmacology of Antibiotics. Clin J Am Soc Nephrol 2019. DOI: 10.2215/CJN.08140718][Levison M.E, Levison J.H. Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infect Dis Clin North Am 2009; 23 (4):791-vii.][Ventola C.L. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther 2015; 40 (4): 277-83.][Blair J.M.A, Webber M.A, Baylay A.J et al. Molecular mechanisms of antibiotic resistance. Nature Rev Microbiol 2015; 13 (1): 42-51.][Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-7.][Aldred K.J, Kerns R.J, Osheroff N. Mechanism of Quinolone Action and Resistance. Biochemistry 2014; 53 (10): 1565--74.][Blondeau J.M, Zhao X, Hansen G, Drlica K. Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45 (2): 433-8.][Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003; 52: 11-7.][Barber A, Norton J, Spivak A, Mulvey M. Urinary tract infections: Current and emerging management strategies. Clin Infect Dis 2013; 57: 719-24.][VanScoy B.D, McCauley J, Ellis-Grosse E.J et al. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model. Antimicrob Agents Chemother 2015; 59 (12): 7170-7.][Novelli A, Rosi E. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemother 2017; 29 (Supp1.): 10-8.][Dalhoff A, Schubert S, Venteb A. Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-b-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections. Antimicrob Agents Chemother 2017; 61 (5): e02446-16.][Davis S.S. Formulation strategies for absorption windows. Drug Discov Today 2005; 10 (4): 249-57.][Arza R.A, Gonugunta C.S, Veerareddy P.R. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. AAPS Pharm Sci Tech 2009; 10 (1): 220-6.][Harder S, Fuhr U, Beermann D, Staib A.H. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule. Br J Clin Pharmacol 1990; 30 (1): 35-9.][Lopes C.M, Bettencourt C, Rossi A et al. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharmaceut 2016; 510: 144-58.][Fourcroy J.L, Berner B, Chiang Y.K et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005; 49 (10): 4137-43.][Hickerson A.D, Carson C.C. The treatment of urinary tract infections and use of ciprofloxacin extended release. Expert Opin Investig Drugs 2006; 15 (5): 519-32.][Mirone V, Fusco F, Taglialatela D et al. Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections. J Chemother 2009; 21 (6): 651-60.][Иремашвили В.В. Новое в лечении инфекций мочевых путей: ципрофлоксацин с замедленным высвобождением. РМЖ. 2008; 16 (5): 312-5. @@Iremashvili V.V. New in the treatment of urinary tract infections: sustained release ciprofloxacin. RMJ 2008; 16 (5): 312-5 (in Russian)][Talan D.A et al. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol 2004; 171 (2 Pt 1): 734-9.][Rasko D.A, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010; 9 (2): 117-28.][Cantas L, Shah S.Q.A, Cavaco L.M et al. A brief multi-disciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiota. Front Microbiol 2013; 4: 1-14.][Bjarnsholt T, Ciofu O, Molin S et al. Applying insights from biofilm biology to drug development - can a new approach be developed. Nature Rev Drug Discovery 2013; 12: 791-808.]